Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652359 | 0.96 | CTRB1 (0.41) | F10CTRB1F2PRSS1PLAU | |
| Trifluoroacetic Acid SCHEMBL5649090 | 0.95 | F10 (0.41) | F10CTRB1F2PRSS1OPRM1 | |
| SCHEMBL5648155 | 0.95 | KMT2A (0.41) | F10F2PRSS1PLAUPLG | |
| SCHEMBL5648073 | 0.94 | CTRB1 (0.41) | F10CTRB1F2PRSS1PLAU | |
| SCHEMBL5645162 | 0.93 | PLAU (0.42) | F10CTRB1F2PRSS1PLAU | |
| SCHEMBL5645835 | 0.93 | PLAU (0.45) | F10F2PRSS1PLAUPLG | |
| SCHEMBL5650568 | 0.92 | F10 (0.42) | F10F2PRSS1PLAU | |
| SCHEMBL5648219 | 0.91 | FNTA (0.43) | F10F2PRSS1PLAUPLG | |
| SCHEMBL5647812 | 0.91 | PLAU (0.42) | F10CTRB1F2PRSS1PLAU | |
| SCHEMBL5649906 | 0.90 | PLAU (0.44) | F10F2PRSS1PLAUF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | claimed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | claimed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | claimed |
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | F10 10/4885CTRB1 259/4885F2 2/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | F10 15/4885CTRB1 208/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.